A Multicenter Phase II Study of Twice|Weekly Bortezomib plus ...

A Multicenter Phase II Study of Twice-Weekly Bortezomib plus ...

Single-agent bortezomib (B) has shown activity in heavily pretreated patients with relapsed/refractory indolent lymphoma. On the basis of these findings, ...

A Multicenter Phase II Study of Twice-Weekly Bortezomib plus ...

Abstract. Single-agent bortezomib (B) has shown activity in heavily pretreated patients with relapsed/refractory indolent lymphoma.

Multicenter Randomized Phase II Study of Weekly or Twice-Weekly ...

PurposeTo determine overall response rate (ORR), time to progression (TTP), and duration of response (DOR) with twice-weekly/weekly bortezomib plus ...

Multicenter Phase II Study of Bortezomib in Patients With Relapsed ...

PurposeEvaluate response rate, duration of response (DOR), time-to-progression (TTP), overall survival (OS), and safety of bortezomib treatment in patients ...

A Multicenter Phase II Study of Twice-Weekly Bortezomib plus ...

Abstract. Single-agent bortezomib (B) has shown activity in heavily pretreated patients with relapsed/refractory indolent lymphoma. On the basis of these.

A Multicenter Phase II Study of Twice-Weekly Bortezomib plus ...

A phase II study of B combined with rituximab in patients with relapsed follicular lymphoma shows the feasibility, long-term efficacy, and excellent ...

A phase 2 study of bortezomib in relapsed, refractory myeloma

Patients received 1.3 mg of bortezomib per square meter of body-surface area twice weekly for 2 weeks, followed by 1 week without treatment, for up to eight ...

Randomized, multicenter, phase 2 study (EVOLUTION) of ...

Randomized phase III study of pegylated liposomal doxorubicin plus ... Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed ...

Multicenter randomized phase II study of weekly or twice-weekly ...

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B- ...

eCommons@AKU

Multicenter Randomized Phase II Study of Weekly or. Twice-Weekly Bortezomib Plus Rituximab in Patients With. Relapsed or Refractory Follicular or Marginal- ...

A Multicenter Phase II Study of Twice-Weekly Bortezomib plus ...

Request PDF | A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up ...

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Patients received 1.3 mg of bortezomib per square meter of body-surface area twice weekly for 2 weeks, followed by 1 week without treatment, for up to eight ...

"Multicenter randomized phase II study of weekly or twice-weekly ...

Conclusion: Both bortezomib plus rituximab regimens seem feasible in relapsed or refractory indolent lymphomas. The more convenient weekly combination regimen ...

Randomized, multicenter, phase 2 study (EVOLUTION) of ...

Randomized phase III study of pegylated liposomal doxorubicin plus ... CB Reeder, DE Reece, V Kukreti, et al. Once- versus twice-weekly bortezomib ...

Efficacy and safety of once-weekly and twice-weekly bortezomib in ...

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal ...

Phase I Trial of Weekly and Twice-Weekly Bortezomib with ...

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal ...

Multi-center phase II trial of bortezomib and rituximab maintenance ...

CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude ...

Efficacy and safety of once-weekly and twice-weekly bortezomib in ...

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular ...

Phase II study of bortezomib–dexamethasone alone or with added ...

Introduction. Bortezomib (VELCADE) plus dexamethasone has been shown to be effective and well tolerated in patients with multiple myeloma (MM). The regimen is ...

A Multicenter Phase II Study of Twice-Weekly Bortezomib plus ...

Figures for A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up.